CA2241051A1 - Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation - Google Patents

Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation Download PDF

Info

Publication number
CA2241051A1
CA2241051A1 CA002241051A CA2241051A CA2241051A1 CA 2241051 A1 CA2241051 A1 CA 2241051A1 CA 002241051 A CA002241051 A CA 002241051A CA 2241051 A CA2241051 A CA 2241051A CA 2241051 A1 CA2241051 A1 CA 2241051A1
Authority
CA
Canada
Prior art keywords
protein
therapeutic
subject
targeting
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002241051A
Other languages
English (en)
Inventor
Edwin L. Madison
Jeffrey W. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2241051A1 publication Critical patent/CA2241051A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un agent ciblé thérapeutique ou diagnostique comprenant (a) une entité fonctionnelle thérapeutique ou diagnostique liée à un des éléments suivants: (a) un imitateur de peptide isolé qui lie de manière spécifique une cible sélectionnée; (b) un acide polyamino isolé, optimisé, à haute affinité qui lie de manière spécifique une cible sélectionnée; (c) une boucle de surface de protéine isolée qui lie de manière spécifique une cible sélectionnée, ladite boucle de surface de protéine n'étant pas endogène à l'entité fonctionnelle. Cette invention concerne également des procédés de ciblage permettant d'orienter des agents thérapeutiques ou de diagnostic sur une cible, un procédé de ciblage d'un agent thérapeutique sur une plaquette à l'aide desdits agents et des procédés de traitement de maladies et de dérèglements associés aux caillots de sang. On décrit plus spécifiquement une protéine de ciblage de recombinaison dans laquelle la boucle de surface est le HCDR3 de l'anticorps monoclonal Fab-9, la deuxième protéine étant un activateur tissulaire humain du plasminogène (t-PA) et la cible étant une glycoprotéine de plaquette GPII/IIIa (intégrine ¿.alpha.?IIb¿.beta.?I).
CA002241051A 1995-12-21 1996-12-19 Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation Abandoned CA2241051A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US902895P 1995-12-21 1995-12-21
US60/009,028 1995-12-21

Publications (1)

Publication Number Publication Date
CA2241051A1 true CA2241051A1 (fr) 1997-10-23

Family

ID=21735166

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002241051A Abandoned CA2241051A1 (fr) 1995-12-21 1996-12-19 Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation

Country Status (5)

Country Link
EP (1) EP0888381A4 (fr)
JP (1) JP2000506854A (fr)
AU (1) AU1821397A (fr)
CA (1) CA2241051A1 (fr)
WO (1) WO1997039021A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
WO2001017563A2 (fr) * 1999-09-08 2001-03-15 Bayer Aktiengesellschaft Ciblage de medicament induit par l'integrine
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
AU2002254691B8 (en) 2001-04-23 2008-02-14 Mallinckrodt Inc. Tc and Re labeler radioactive glycosylated octreotide derivatives
WO2007003010A1 (fr) * 2005-07-05 2007-01-11 Baker Medical Research Institute Agent anticoagulant et son utilisation
JP2010511397A (ja) * 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339445C (fr) * 1986-11-12 1997-09-09 The General Hospital Corporation Molecules d'immunoglobuline hybride recombinante et methode d'utilisation
ATE145428T1 (de) * 1990-12-14 1996-12-15 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same

Also Published As

Publication number Publication date
WO1997039021A1 (fr) 1997-10-23
EP0888381A1 (fr) 1999-01-07
EP0888381A4 (fr) 2001-10-17
JP2000506854A (ja) 2000-06-06
AU1821397A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
US5011686A (en) Thrombus specific conjugates
Haber et al. Innovative approaches to plasminogen activator therapy
Lijnen et al. Strategies for the improvement of thrombolytic agents
US5632986A (en) Phospholipid-targeted thrombolytic agents
US5550213A (en) Inhibitors of urokinase plasminogen activator
US8445245B2 (en) Mutant MT-SP1 proteases with altered substrate specificity or activity
US7939304B2 (en) Mutant MT-SP1 proteases with altered substrate specificity or activity
JPH07507448A (ja) 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
US20090169553A1 (en) Novel Protein Fusion/Tag Technology
US6660492B1 (en) Chimeric serine proteases
JPH05508664A (ja) リン脂質標的血栓溶解剤
CA2241051A1 (fr) Agents cibles therapeutiques ou diagnostiques et leurs procedes de preparation et d'utilisation
EP0804580B1 (fr) Anticorps recombine se liant au calcium contre la proteine c
Mesters et al. Generation of fusion proteins for selective occlusion of tumor vessels
WO1991016353A1 (fr) Derives d'anticorps specifiques au thrombus
EP0703923B1 (fr) Peptides derives du facteur vii
RU2283863C2 (ru) Рекомбинантное производное стафилокиназы, его получение и применение
Kumar et al. Specific molecular interaction sites on factor VII involved in factor X activation
EP0942996B1 (fr) Agents thrombolytiques a activite antithrombotique
CN1970746B (zh) 具有抗血小板聚集活性的重组组织型纤溶酶原激活物的双功能变异体
US20120058537A1 (en) Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
Verstraete The search for the ideal thrombolytic agent
Swenson et al. Fibrolase
JPH01165379A (ja) 新規化合物、その製法及びそれを含む医薬組成物
CN1381460A (zh) 一种新型纤溶酶原激活剂(tpa)突变体的结构与用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead